VitalCare Signs LOI for Diabetes Treatment Centers in Indiana
Posted on: Tuesday, 29 April 2008, 09:01 CDT
VitalCare Diabetes Treatment Centers, Inc. (Pink Sheets:VDTI), a Nevada corporation, today announced they have signed a letter of intent to open two new Diabetes Treatment and Wound Care Centers in Indiana. The centers will be administering the FDA approved iCAT treatment for diabetes and related wound care for Type 1 and Type 2 diabetes patients. These are the first of a series of centers to be opened in the Midwest of the United States.
Jimmy McDougald, CEO of VitalCare, stated, "This is the beginning of our Midwest launch and we are excited to be offering iCAT therapy to diabetics in this region."
Tristan V. Voth-Stonger, MD, Executive Vice President & CMO of VitalCare, has identified the centers (Peru, IN and Indianapolis, IN) and structured the LOI, and stated, "These facilities were handpicked for their strategic locations and capacity for growth."
About VitalCare Diabetes Treatment Centers, Inc.
VitalCare Diabetes Treatment Centers, Inc. is a company specializing in providing Administrative, Marketing, Business Development, Strategic Planning, Clinical Oversight and Clinical Management Services to the Diabetes Healthcare Sector, with an emphasis in bringing "Cutting Edge" medical devices and healthcare services direct to consumers, focusing on an emerging FDA approved, US and European Patented technology and treatment intervention for treating Type 1 and Type 2 Diabetes known as "Intracellular Activation Therapy (iCAT)."
Safe Harbor Statement: Forward-looking statements in this release with respect to VitalCare Diabetes Treatment Centers, Inc.'s business, financial condition and results of operations, as well as matters of timing and the prospective terms of the transaction described are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond VitalCare Diabetes Treatment Centers, Inc.'s control with respect to market acceptance of their technology and/or products, whether financing will be available, the effect of the application of acquisition accounting policies as well as certain other risk factors which are and may be detailed from time to time in VitalCare's filings with the Securities and Exchange Commission.
Source: Business Wire
Related Articles
- Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
- VAP Test Helps Researchers Uncover Best Cholesterol Lowering Treatment for Type II Diabetes
- Joslin Diabetes Center Launches National Clinical Trial To Explore If Anti-Inflammatory Drug Can Improve Glucose Control in Type 2 Diabetes
- RejuvaCell's Breakthrough Stem Cell Therapy Demonstrates Potential to Revolutionize Treatment for Type-2 Diabetes
- BYETTA(R) (Exenatide) Approved for Treatment of Type 2 Diabetes By European Commission
- GlaxoSmithKline Announces FDA Approval and the Launch of Avandamet(R) (Rosiglitazone Maleate and Metformin HCl) As Initial Therapy in the Treatment of Type 2 Diabetes
- Depomed Data Published in Diabetes Care on Glumetza, an FDA-Approved Treatment for Type II Diabetes
- Bristol-Myers Squibb Statement on Muraglitazar, an Investigational Oral Treatment for Type 2 Diabetes
- Nektar Therapeutics Reports Exubera(R) Receives Positive Opinion From CHMP for the Treatment of Type 1 and Type 2 Diabetes
- Innodia Inc Advances Lead Drug Candidate for Treatment of Type 2 Diabetes
 |
 |
User Comments (0)
RSS Feeds